Related Experiment Videos
Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer
L Crinò1, C Calandri, A Maestri
1Medical Oncology Unit, Oncology Department, Bellaria Hospital, Bologna, Italy.
Oncology (Williston Park, N.Y.)
|April 17, 2001
Abstract:
A number of randomized clinical trials now support the conclusion that the combined-modality regimen that includes gemcitabine (Gemzar) and cisplatin (Platinol) may improve survival in disseminated non-small-cell lung cancer. Cisplatin is considered to be the "backbone" of this combination chemotherapy due to its proven activity. The regimen of gemcitabine and cisplatin has been tested and is now considered among the most active combinations in the treatment of disseminated non-small-cell lung cancer.